Skip to content
The Great News – Lifestyle
Home
Sample Page
Author:
Nanoscope Therapeutics
Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene therapy, MCO-010
July 7, 2026
Nanoscope Therapeutics Selects InspiroGene by McKesson to Support Distribution of Novel Retinal Therapy
May 27, 2026
Nanoscope Therapeutics to Present Advanced Clinical and Manufacturing Findings at ASGCT 2026 Annual Meeting
May 11, 2026
Nanoscope Therapeutics Announces Participation at Eyecelerator® and ARVO 2026 Annual Meetings
April 29, 2026
Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness
April 1, 2026
Nanoscope Therapeutics Receives Orphan Drug Designation in Saudi Arabia for MCO-010, Expands Global Regulatory Leadership in Vision Restoration
March 30, 2026
Nanoscope Therapeutics Announces Publication of New Study Highlighting Functional Vision Assessment in Retinal Disease
March 23, 2026